COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #63
Source   PDF   Share   Tweet
See all 155 studies
Early treatment study
Chen et al., medRxiv, doi:10.1101/2020.06.19.20136093 (Preprint)
Efficacy and safety of ch loroquine or hydroxych loroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
Significantly faster clinical recovery and shorter time to RNA negative (from 7.0 days to 2.0 days (HC Q), p=0.01. 67 patients with mild/moderate cases.
time to viral-, ↓72.0%, p=0.01, median time to PCR-
Source   PDF   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.